See up to 3 months of ASND. The 7-day demo opens the 1M and 3M ranges and puts ASND on your watchlist.
Start 7-day demoLatest ASND insider trades
About Ascendis Pharma A/S (ASND)
Ascendis Pharma A/S is an SEC registrant, filing under CIK 0001612042, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
ASND Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 2,000 | $493K |
| Open-market sale | 2 | 3,236 | $873K |
| Grant or award | 1 | 9,160 | |
ASND insider transactions (Form 4)
169 Form 4 filings on record, the earliest from May 12, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jean Jacques Bienaime - Director | Derivative | Warrants | 9,160 | - footnote F2 | - | |
| Jean Jacques Bienaime - Director | Grant or award | Warrants | 9,160 | - footnote F2 | - | |
| ||||||
| Mads Bodenhoff - Officer | Option exercise | Ordinary Shares | 3,000 | $110.00 | $330K | |
| Mads Bodenhoff - Officer | Open-market sale | Ordinary Shares | 3,000 | $270.19 | $811K | |
| Mads Bodenhoff - Officer | Option exercise | Warrants | 3,000 | $0.00 | - | |
| Lars Holtug - Director | Open-market sale | Ordinary Shares | 236 | $264.13 | $62K | |
| Jean Jacques Bienaime - Director | Open-market purchase | Ordinary Shares | 1,100 | $245.85 footnote F1 | $270K | |
| Jean Jacques Bienaime - Director | Open-market purchase | Ordinary Shares | 900 | $246.91 footnote F2 | $222K | |
| ||||||
| Scott Thomas Smith - Officer | Open-market purchase | Ordinary Shares | 100 | $219.00 | $22K | |
| Jean Jacques Bienaime | Open-market purchase | Ordinary Shares | 200 | $223.76 | $45K | |
| Jean Jacques Bienaime | Open-market purchase | Ordinary Shares | 200 | $222.30 | $44K | |
| Jean Jacques Bienaime | Open-market purchase | Ordinary Shares | 100 | $223.50 | $22K | |
| Scott Thomas Smith - Officer | Open-market purchase | Ordinary Shares | 250 | $223.32 | $56K | |
| Jean Jacques Bienaime | Open-market purchase | Ordinary Shares | 200 | $236.24 footnote F1 | $47K | |
| Jean Jacques Bienaime | Open-market purchase | Ordinary Shares | 200 | $239.37 footnote F2 | $48K | |
| ||||||
| Flemming Steen Jensen - Officer | Open-market sale | Ordinary Shares | 19,460 | $238.49 | $4.64M | |
Recent ASND Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Bodenhoff Mads | Officer | 3,000 | $811K | View on EDGAR | |
| HOLTUG LARS | Director | 236 | $62K |
ASND insider trading FAQ
What is the latest insider trade for ASND?
Ascendis Pharma A/S (ASND) had 4 insider filings in the last 90 days, with the most recent on 2026-09-28. The full record for ASND runs to 9 Form 4 filings, the earliest from 2026-05-12. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ASND stock?
2 insider purchases of ASND were filed in the last 90 days, totaling $493K.
How many insiders are selling ASND stock?
2 insider sales of ASND were filed in the last 90 days, totaling $873K.
Where can I see ASND SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ASND Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
9The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Jean Jacques Bienaime view on EDGAR
- - Mads Bodenhoff view on EDGAR
- - Lars Holtug view on EDGAR
- - Jean Jacques Bienaime view on EDGAR
- - Scott Thomas Smith view on EDGAR
- - Jean Jacques Bienaime view on EDGAR
- - Scott Thomas Smith view on EDGAR
- - Jean Jacques Bienaime view on EDGAR
- - Flemming Steen Jensen view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where ASND's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ASND with a 7-day demo
- ASND on your watchlist
- Every ASND Form 4 filing on record
- Up to 3 months of ASND price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
